GB1601744A - Processes for the purification of interferon certain new and useful intermediates formed therein the purified interferon thus produced and pharmaceutical compositions containing - Google Patents
Processes for the purification of interferon certain new and useful intermediates formed therein the purified interferon thus produced and pharmaceutical compositions containing Download PDFInfo
- Publication number
- GB1601744A GB1601744A GB17225/78A GB1722578A GB1601744A GB 1601744 A GB1601744 A GB 1601744A GB 17225/78 A GB17225/78 A GB 17225/78A GB 1722578 A GB1722578 A GB 1722578A GB 1601744 A GB1601744 A GB 1601744A
- Authority
- GB
- United Kingdom
- Prior art keywords
- interferon
- process according
- products
- buffer
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 201
- 108010050904 Interferons Proteins 0.000 title claims abstract description 201
- 229940079322 interferon Drugs 0.000 title claims abstract description 199
- 238000000034 method Methods 0.000 title claims description 70
- 230000008569 process Effects 0.000 title claims description 51
- 238000000746 purification Methods 0.000 title claims description 18
- 239000000543 intermediate Substances 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 112
- 230000000694 effects Effects 0.000 claims abstract description 93
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 89
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 89
- 239000002157 polynucleotide Substances 0.000 claims abstract description 80
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 4
- 239000000872 buffer Substances 0.000 claims description 53
- 229920002684 Sepharose Polymers 0.000 claims description 52
- 238000003795 desorption Methods 0.000 claims description 37
- 229920002307 Dextran Polymers 0.000 claims description 34
- 239000003463 adsorbent Substances 0.000 claims description 30
- 239000003446 ligand Substances 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 10
- 239000007983 Tris buffer Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 229920000936 Agarose Polymers 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 238000011835 investigation Methods 0.000 claims description 5
- 229920002521 macromolecule Polymers 0.000 claims description 5
- 230000000717 retained effect Effects 0.000 claims description 4
- 239000012149 elution buffer Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003367 polycyclic group Chemical group 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 150000004804 polysaccharides Polymers 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 238000007669 thermal treatment Methods 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 93
- 238000000926 separation method Methods 0.000 abstract description 2
- 239000012264 purified product Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000008878 coupling Effects 0.000 description 14
- 238000010168 coupling process Methods 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 238000001042 affinity chromatography Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000010359 Newcastle Disease Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 235000019256 formaldehyde Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical compound OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 238000011403 purification operation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 229930183912 Cytidylic acid Natural products 0.000 description 1
- 208000000993 Dendritic Keratitis Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 229940009493 gel-one Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000043 immunodepressive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7713255A FR2389380B1 (enrdf_load_stackoverflow) | 1977-05-02 | 1977-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1601744A true GB1601744A (en) | 1981-11-04 |
Family
ID=9190209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB17225/78A Expired GB1601744A (en) | 1977-05-02 | 1978-05-02 | Processes for the purification of interferon certain new and useful intermediates formed therein the purified interferon thus produced and pharmaceutical compositions containing |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS53139714A (enrdf_load_stackoverflow) |
| CH (1) | CH633716A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2819297A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2389380B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1601744A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117423A (en) * | 1979-04-20 | 2000-09-12 | Schering Corporation | Highly purified species of human leukocyte interferon |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN150740B (enrdf_load_stackoverflow) * | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| FI77877C (fi) * | 1979-04-20 | 1989-05-10 | Technobiotic Ltd | Foerfarande foer framstaellning och rening av human le-formig interferonprotein. |
| US4278661A (en) * | 1979-10-12 | 1981-07-14 | E. I. Du Pont De Nemours And Company | Purification of interferon |
| US4362155A (en) * | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
-
1977
- 1977-05-02 FR FR7713255A patent/FR2389380B1/fr not_active Expired
-
1978
- 1978-05-02 CH CH473978A patent/CH633716A5/fr not_active IP Right Cessation
- 1978-05-02 DE DE19782819297 patent/DE2819297A1/de not_active Withdrawn
- 1978-05-02 GB GB17225/78A patent/GB1601744A/en not_active Expired
- 1978-05-02 JP JP5243578A patent/JPS53139714A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117423A (en) * | 1979-04-20 | 2000-09-12 | Schering Corporation | Highly purified species of human leukocyte interferon |
| US6410697B1 (en) | 1979-04-20 | 2002-06-25 | Schering Corporation | Process for purifying human leukocyte interferon |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2389380A1 (enrdf_load_stackoverflow) | 1978-12-01 |
| CH633716A5 (en) | 1982-12-31 |
| FR2389380B1 (enrdf_load_stackoverflow) | 1980-02-29 |
| DE2819297A1 (de) | 1978-11-16 |
| JPS53139714A (en) | 1978-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4257938A (en) | Purification method of human fibroblast interferon | |
| US4172071A (en) | Chromophore blue adsorbent method for the purification of preparations having an interferon type activity | |
| FI72124C (fi) | Foerfarande foer tillvaratagande av interferon. | |
| JPH07103044B2 (ja) | Ｃ１不活性化剤を含有する医薬の調製方法 | |
| JP2644946B2 (ja) | ＩｇＧ− モノクロナール抗体の精製方法及びその使用方法 | |
| JP3438735B2 (ja) | 上清ｉｖ、特にｉｖ−４またはコーンフラクションｖまたはそれと類似の上清または画分からヒトアルブミンを単離する方法 | |
| CA1133898A (en) | Purification of interferon | |
| EP0094672B1 (en) | Purification method of human interferon | |
| JPS6098988A (ja) | Ｌｐｆ−ｈａの精製法 | |
| JPS63503352A (ja) | タンパク質の精製 | |
| JPH06321994A (ja) | アンチトロンビン調製物およびその調製方法 | |
| JPS58159417A (ja) | 均一なヒトのインタ−フエロン及びその製造方法 | |
| GB1601744A (en) | Processes for the purification of interferon certain new and useful intermediates formed therein the purified interferon thus produced and pharmaceutical compositions containing | |
| JPH03501085A (ja) | 化学的プロセス | |
| JPH0479359B2 (enrdf_load_stackoverflow) | ||
| JPS62259596A (ja) | ハイブリツドタンパク質の精製方法 | |
| US4526782A (en) | Process for recovering interferon | |
| FUNATSU et al. | Structure and Toxic Function of Ricin I Purification Procedures of Ricin D | |
| US7365173B2 (en) | Method for the production of pure virally inactivated butyrylcholinesterase | |
| JPS641118B2 (enrdf_load_stackoverflow) | ||
| WO1984003104A1 (en) | Dna synthesis-repressing substance | |
| JPS62209099A (ja) | 殺菌された抗プラスミン溶液の製造方法 | |
| EP0318302A1 (en) | Proteinaceous compositions | |
| JPS6168422A (ja) | Ｌｐｆ−ｈａの精製方法 | |
| JPS58189119A (ja) | 尿性抗腫瘍蛋白 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed | ||
| PCNP | Patent ceased through non-payment of renewal fee |